Business Context and Reporting Period
This Form 10-Q covers The Procter & Gamble Company for the quarterly period ended September 30, 2003. The Company operates globally across five primary segments: Fabric & Home Care, Baby & Family Care, Beauty Care, Health Care, and Snacks & Beverages. A defining event for this period was the acquisition of a controlling interest (81%) in Wella AG, a professional and retail hair care and cosmetics company, completed in September 2003 for approximately $5.1 billion.
Key Financial Metrics
| Metric | Q1 2004 (Sep 30, 2003) | Q1 2003 (Sep 30, 2002) |
|---|---|---|
| Net Sales | $12,195 million | $10,796 million |
| Operating Income | $2,643 million | $2,179 million |
| Net Earnings | $1,761 million | $1,464 million |
| Diluted EPS | $1.26 | $1.04 |
| Operating Cash Flow | $1,606 million | $2,010 million |
| Free Cash Flow | $1,242 million | $1,729 million |
| Total Debt (Current + Long-Term) | $17,279 million | $13,647 million (approx. prior year) |
| Cash and Equivalents | $4,049 million | $4,703 million |
| Gross Margin | 51.8% | 49.2% |
| Operating Margin | 21.7% | 20.2% |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13% to $12.20 billion, driven by a 12% increase in unit volume and a 3% positive foreign exchange impact. The Wella acquisition contributed significantly to the Beauty Care segment's 21% volume growth.
- Profitability: Net earnings rose 20% to $1.76 billion. This was driven by volume growth, lower manufacturing costs, and the absence of $113 million in restructuring charges that impacted the prior year. Gross margin expanded 260 basis points.
- Cash Flow: Operating cash flow decreased to $1.61 billion from $2.01 billion due to increased working capital requirements (specifically accounts receivable and inventory) and the timing of the Prilosec OTC launch.
- Balance Sheet: Total assets increased to $50.5 billion from $43.7 billion (June 30, 2003), primarily due to the Wella acquisition. Goodwill increased by $3.82 billion to $15.2 billion. Short-term debt increased significantly to fund the acquisition.
Guidance, Outlook, and Risks
- Outlook: Management expects Fabric & Home Care earnings growth to improve over the remainder of the fiscal year. Health Care results are expected to return to normal consumption levels in future quarters following the one-time pipeline impact of the Prilosec OTC launch. Snacks & Beverages pricing is expected to be neutral or slightly negative for the balance of the year due to competitive coffee pricing.
- Acquisition Integration: The Company is finalizing the purchase price allocation for Wella, which may result in adjustments to asset values and goodwill. Pro forma results suggest diluted EPS of $1.24 for the quarter if Wella had been acquired at the beginning of the fiscal year.
- Risks: Business and market uncertainties could affect results. The Company faces heavy competitive activity in core categories and commodity price increases, though these were offset by cost savings in this quarter. The Company has entered into multi-year service contracts estimated at $3.6 billion.
- Restructuring: The multi-year restructuring program initiated in 1999 is substantially complete, with a remaining reserve of $335 million expected to be settled by the end of 2004.
Investor Verification Checklist
- Wella Acquisition Impact: Verify the final purchase price allocation and the specific contribution of Wella to the Beauty Care segment's future earnings.
- Working Capital Trends: Monitor the sustainability of the increase in accounts receivable and inventory days on hand, which reduced operating cash flow.
- Prilosec OTC Sustainability: Assess whether Health Care sales growth can be maintained after the initial launch surge subsides in subsequent quarters.
- Debt Levels: Review the increase in short-term debt used to finance the Wella acquisition and the Company's plan to manage leverage.
- Competitive Pricing: Evaluate the impact of aggressive pricing in the coffee category and competitive promotions in fabric care on future margins.